Lung Carcinoma Clinical Trial
Official title:
The BE WELL Study: Black Raspberry Beverage Working to Prevent Lung Cancer
Verified date | November 2023 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well black raspberry nectar works in changing the gut microbiome and in reducing inflammatory processes that may lead to lung cancer. Studying the effects of black raspberry beverage on inflammation may help doctors find strategies to reduce the risk of developing lung cancer.
Status | Completed |
Enrollment | 96 |
Est. completion date | June 13, 2021 |
Est. primary completion date | May 13, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years to 77 Years |
Eligibility | Inclusion Criteria: - Have a 30 pack-year smoking history - Be either a current smoker or a former smoker that quit in the last 15 years. Any individual who is currently smoking and has smoked more than 100 cigarettes in their lifetime will be identified as a current smoker - Agree to consume a standardized vitamin / mineral supplement and avoid other nutritional, dietary or alternative medications / supplements / probiotics for the duration of the study - Agree to follow a berry-free / controlled phenolic diet and to document consumption of polyphenolic foods each day of the study using a simple daily form Exclusion Criteria: - Person has an allergy to any berries, pectin, or food colorants apples,as well as kiwi fruit, strawberries, soy sauce, pine nuts, almonds, cherries, peaches, blackberries, pears - Person states that they are not a: - Current smoker: active cigarette smoker who has smoked more than 30 pack-years in the last 15 years OR - Former smoker: not a current smoker active cigarette smoker who has smoked more than 30 pack years in the last 15 years - Person is unwilling to follow a berry-free/controlled polyphenol diet while on study - Person has history of metabolic disorders (diabetes, hyper/hypo-thyroidism, etc.); digestive illness which may result in nutrient malabsorption (Crohn's disease, Celiac, renal/hepatic insufficiency, short bowel, etc.); disorders that affect connective tissues; or blood clotting disorders - Person has allergy or food intolerance to ingredients in study products (black raspberries or other berries) - Person is on a regimen of any of the following medications: - Immunosuppressants, bisphosphonates, or steroids. - Anticoagulants (warfarin, apixaban, dabigatran, and rivaroxaban) - Probiotics - Person is undergoing treatment for cancer in any form - Person is currently pregnant or nursing or plans to become pregnant during this study - Person plans to enter smoking cessation or change their smoking status during the course of the study |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rates | Recruitment rates will be defined as the proportion of screened accrued relative to those approached. Successful recruitment rates will be defined as >= 10% of participants approached agree to participate. | Up to 3 years | |
Primary | Study adherence | Study adherence will be defined as the percent of the biospecimens collected at the end of the study period, with a compliance goal of 60%. Will track the monthly collection of data and document reasons for missing any scheduled collection dates. The proportions of missing information at each time point will be calculated. Descriptive statistics will examine the distribution of all patient and treatment characteristics, overall and by patient and disease characteristics. | Up to 3 years | |
Primary | Inflammatory markers found in nasal brushings | Evaluated by ribonucleic acid sequencing. | Up to 3 years | |
Primary | Changes in stool microbe relative abundances | Evaluated by metagenomic whole sequencing. | Up to 3 years | |
Primary | Biologic responses to the black raspberry (BRB) nectar | Samples of urine, stool. and blood will be analyzed for BRB phytochemicals (ellagitannins, ellagic acid, quercetin glycosides, anthocyanins) and their metabolites (urolithins, quercetin glucuronides/sulfates, methylated anthocyanins). | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04931017 -
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Not yet recruiting |
NCT06038526 -
Evaluation of Canakinumab in High-Risk Former-Smokers
|
Phase 2 | |
Terminated |
NCT02856581 -
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
|
Phase 3 | |
Completed |
NCT04922697 -
Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study
|
N/A | |
Recruiting |
NCT04644952 -
The Rise in Robotic Atypical Segmentectomies
|
||
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Recruiting |
NCT05407168 -
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
|
N/A | |
Recruiting |
NCT02408861 -
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Recruiting |
NCT03709953 -
Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03267524 -
Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers
|
N/A | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT02237183 -
Iloprost in Preventing Lung Cancer in Former Smokers
|
Phase 1 | |
Recruiting |
NCT04783168 -
Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study
|
N/A | |
Completed |
NCT04635761 -
Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening
|
N/A | |
Recruiting |
NCT06445192 -
Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial
|
N/A | |
Active, not recruiting |
NCT03164486 -
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
|
Early Phase 1 | |
Recruiting |
NCT05802186 -
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
|
N/A | |
Active, not recruiting |
NCT01696968 -
Screening for Lung Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|